Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2016New England Journal of MedicineOpen Access

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSteven P. MarsoSBStephen C. BainACAgostino Consoli

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Marso et al. (2016) studied this question.

synapsesocial.com/papers/6aabcd33bf14f972179725c7https://doi.org/10.1056/nejmoa1607141
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization2009 · 78 citations
  2. 2Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide2015 · 1,092 citations
  3. 3Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,282 citations